Rein Therapeutics Inc.
NCM: RNTXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Rein Therapeutics Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get RNTX Z-Score →About Rein Therapeutics Inc.
Healthcare
Biotechnology
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.
📊 Fundamental Analysis
Rein Therapeutics Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -139.9%, which indicates that capital utilization is currently under pressure.
At a current price of $1.49, RNTX currently sits at the 34th percentile of its 52-week range (Range: $1.02 - $2.40).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$41.78M
Trailing P/E
--
Forward P/E
--
Beta (5Y)
1.40
52W High
$2.40
52W Low
$1.02
Avg Volume
112K
Day High
Day Low